These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 34015517)
1. The potential role of miRNA therapies in spinal muscle atrophy. Gandhi G; Abdullah S; Foead AI; Yeo WWY J Neurol Sci; 2021 Aug; 427():117485. PubMed ID: 34015517 [TBL] [Abstract][Full Text] [Related]
2. miRNA in spinal muscular atrophy pathogenesis and therapy. Magri F; Vanoli F; Corti S J Cell Mol Med; 2018 Feb; 22(2):755-767. PubMed ID: 29160009 [TBL] [Abstract][Full Text] [Related]
3. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand? Chen TH Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392694 [TBL] [Abstract][Full Text] [Related]
4. An Overview of the Therapeutic Strategies for the Treatment of Spinal Muscular Atrophy. Li Y; Zeng H; Wei Y; Ma X; He Z Hum Gene Ther; 2023 Mar; 34(5-6):180-191. PubMed ID: 36762938 [TBL] [Abstract][Full Text] [Related]
5. Cell-type-specific miR-431 dysregulation in a motor neuron model of spinal muscular atrophy. Wertz MH; Winden K; Neveu P; Ng SY; Ercan E; Sahin M Hum Mol Genet; 2016 Jun; 25(11):2168-2181. PubMed ID: 27005422 [TBL] [Abstract][Full Text] [Related]
6. Tissue-specific models of spinal muscular atrophy confirm a critical role of SMN in motor neurons from embryonic to adult stages. Laird AS; Mackovski N; Rinkwitz S; Becker TS; Giacomotto J Hum Mol Genet; 2016 May; 25(9):1728-38. PubMed ID: 26908606 [TBL] [Abstract][Full Text] [Related]
7. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape. Wood MJA; Talbot K; Bowerman M Hum Mol Genet; 2017 Oct; 26(R2):R151-R159. PubMed ID: 28977438 [TBL] [Abstract][Full Text] [Related]
8. Therapeutics development for spinal muscular atrophy. Sumner CJ NeuroRx; 2006 Apr; 3(2):235-45. PubMed ID: 16554261 [TBL] [Abstract][Full Text] [Related]
9. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice. Torres-Benito L; Schneider S; Rombo R; Ling KK; Grysko V; Upadhyay A; Kononenko NL; Rigo F; Bennett CF; Wirth B Am J Hum Genet; 2019 Jul; 105(1):221-230. PubMed ID: 31230718 [TBL] [Abstract][Full Text] [Related]
10. A Perturbed MicroRNA Expression Pattern Characterizes Embryonic Neural Stem Cells Derived from a Severe Mouse Model of Spinal Muscular Atrophy (SMA). Luchetti A; Ciafrè SA; Murdocca M; Malgieri A; Masotti A; Sanchez M; Farace MG; Novelli G; Sangiuolo F Int J Mol Sci; 2015 Aug; 16(8):18312-27. PubMed ID: 26258776 [TBL] [Abstract][Full Text] [Related]
11. RNA in spinal muscular atrophy: therapeutic implications of targeting. Singh RN; Seo J; Singh NN Expert Opin Ther Targets; 2020 Aug; 24(8):731-743. PubMed ID: 32538213 [TBL] [Abstract][Full Text] [Related]
12. Calpain Inhibition Increases SMN Protein in Spinal Cord Motoneurons and Ameliorates the Spinal Muscular Atrophy Phenotype in Mice. de la Fuente S; Sansa A; Periyakaruppiah A; Garcera A; Soler RM Mol Neurobiol; 2019 Jun; 56(6):4414-4427. PubMed ID: 30327977 [TBL] [Abstract][Full Text] [Related]
13. Nusinersen ameliorates motor function and prevents motoneuron Cajal body disassembly and abnormal poly(A) RNA distribution in a SMA mouse model. Berciano MT; Puente-Bedia A; Medina-Samamé A; Rodríguez-Rey JC; Calderó J; Lafarga M; Tapia O Sci Rep; 2020 Jul; 10(1):10738. PubMed ID: 32612161 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic strategies for spinal muscular atrophy: SMN and beyond. Bowerman M; Becker CG; Yáñez-Muñoz RJ; Ning K; Wood MJA; Gillingwater TH; Talbot K; Dis Model Mech; 2017 Aug; 10(8):943-954. PubMed ID: 28768735 [TBL] [Abstract][Full Text] [Related]
15. [Treatment of Spinal Muscular Atrophy]. Ishiyama A Brain Nerve; 2023 May; 75(5):507-510. PubMed ID: 37194521 [TBL] [Abstract][Full Text] [Related]
16. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells. Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660 [TBL] [Abstract][Full Text] [Related]
17. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Riessland M; Ackermann B; Förster A; Jakubik M; Hauke J; Garbes L; Fritzsche I; Mende Y; Blumcke I; Hahnen E; Wirth B Hum Mol Genet; 2010 Apr; 19(8):1492-506. PubMed ID: 20097677 [TBL] [Abstract][Full Text] [Related]
18. Cell-Based Therapy for Spinal Muscular Atrophy. Han F; Ebrahimi-Barough S; Abolghasemi R; Ai J; Liu Y Adv Exp Med Biol; 2020; 1266():117-125. PubMed ID: 33105498 [TBL] [Abstract][Full Text] [Related]
19. Temporal and tissue-specific variability of SMN protein levels in mouse models of spinal muscular atrophy. Groen EJN; Perenthaler E; Courtney NL; Jordan CY; Shorrock HK; van der Hoorn D; Huang YT; Murray LM; Viero G; Gillingwater TH Hum Mol Genet; 2018 Aug; 27(16):2851-2862. PubMed ID: 29790918 [TBL] [Abstract][Full Text] [Related]
20. Neurocalcin Delta Suppression Protects against Spinal Muscular Atrophy in Humans and across Species by Restoring Impaired Endocytosis. Riessland M; Kaczmarek A; Schneider S; Swoboda KJ; Löhr H; Bradler C; Grysko V; Dimitriadi M; Hosseinibarkooie S; Torres-Benito L; Peters M; Upadhyay A; Biglari N; Kröber S; Hölker I; Garbes L; Gilissen C; Hoischen A; Nürnberg G; Nürnberg P; Walter M; Rigo F; Bennett CF; Kye MJ; Hart AC; Hammerschmidt M; Kloppenburg P; Wirth B Am J Hum Genet; 2017 Feb; 100(2):297-315. PubMed ID: 28132687 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]